Navigation Links
Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR
Date:10/8/2008

ical studies as planned and that such studies will support the use of HspE7 as a treatment for CIN 1 and CIN 2/3; that we will complete the second protocol for the CIN 1 indication; that Poly-IRC will be useful as a broad immune stimulatory agent and vaccine adjuvant; that we will be able to advance Poly-ICR to generate revenue and for internal development; that Poly-ICR will provide us with near-term revenue opportunity; that Poly-ICR will be useful in the treatment of GW and actinic keratosis; that we will complete development activities and file an IND application in connection with Poly-ICR; that we will finalize manufacturing and formulation protocols and file an IND in connection with Hsp 6/11; that we will be able to execute our corporate restructuring as planned; that we will be able to expand corporate development efforts as planned and that such efforts will produce the desired results; that results from future clinical trials will be consistent with our expectations; that we will raise enough capital (through partnering or otherwise), on reasonable terms and in a timely manner; that we will retain our key personnel; that we will obtain the necessary regulatory approvals related to HspE7, Hsp 6/11 and Poly-ICR in a timely manner; that sufficient HspE7, Hsp 6/11 and Poly-ICR will be available to conduct our planned clinical trials; that we will obtain timely approval from additional Investigational Review Boards; that the results from additional preclinical and clinical work, if any, will be consistent with the results we have already obtained; and that a sufficient number of patients will be available to conduct our planned trials, and that sufficient data will be generated in such trials.

In the event that any of these assumptions prove to be incorrect, or in the event that we are impacted by any of the risks identified above, we may not be able to continue in our business as planned.

For a complete discussion of the assumptions, risks and u
'/>"/>

SOURCE Nventa Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Nventa Appoints John Varian to Board of Directors
9. Nventa Appoints Gordon H. Busenbark to Board of Directors
10. CardioDynamics Provides 2007 Shareholder Meeting Update
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)...  Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the ... of high pressure-based sample preparation systems to the life ... to present at the 2 nd  Global Life ... The Conference will take place at the Warsaw Stock ... Schumacher , President and CEO of PBI, will present ...
(Date:10/1/2014)... City, CA (PRWEB) October 01, 2014 As ... it leaves no room for doubt that this century would ... innovations in the field of medicine science. The fact that ... problems is not unknown to the scientific community. Almost half ... pollution and therefore can be prevented with medical care and ...
(Date:10/1/2014)... 2014 New applications of structures and ... evolved in nature over millennia are featured in a ... for applications in biophotonics in the October issue of ... is published by SPIE, the international society for optics ... the peer-reviewed articles are accessible via open access. , ...
(Date:10/1/2014)... 01, 2014 The U.S. Department of ... Illinois University Edwardsville as part of the Trade Adjustment ... funding is co-administered by the Department of Labor and ... of Labor Thomas E. Perez and Secretary of Education ... job-driven training grants to nearly 270 colleges across the ...
Breaking Biology Technology:Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 2Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 3Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 4Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 2Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 3Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 4
... WASHINGTON, Oct. 5 The Coalition for a,Competitive ... the Food and Drug Administration,s announcement regarding its,"Generic ... consumers, employers, insurers, and policymakers grappling with,how to ... that FDA,and Congress continue to focus on ways ...
... Lexicon,Pharmaceuticals, Inc. (Nasdaq: LXRX ) today announced that ... officer, will present,at the BIO InvestorForum at The Palace ... at 11:00 a.m. Pacific Time. A live webcast ... at http://www.lexpharma.com . An archived version of the,webcast ...
... Pharmasset, Inc.,(Nasdaq: VRUS ) has entered into ... Subject to certain terms and conditions of,the agreement, Horizon ... At its option, Pharmasset may receive a second loan ... loan of $10 million by November 30, 2008,provided conditions ...
Cached Biology Technology:CCPM Issues Statement on FDA's GIVE Initiative 2Lexicon Pharmaceuticals to Present at Bio InvestorForum 2Pharmasset Accesses up to $30 Million of Working Capital 2Pharmasset Accesses up to $30 Million of Working Capital 3
(Date:9/30/2014)... (PCE) in drinking water may increase the risk ... new study led by a Boston University School ... in the journal Environmental Health , compared ... 1,766 women in Cape Cod, Ma., where water ... early 1980s by the installation of vinyl-lined asbestos ...
(Date:9/30/2014)... FRANKFURT. Truffles, along ... world. Because they grow underground, people use trained dogs or ... is not only of interest to gourmets. A group of ... University Frankfurt have discovered that the smell of white truffles ... truffle fruiting bodies. , White truffles from the Piedmont region ...
(Date:9/30/2014)... Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich report that ... cells more sensitive to chemotherapeutic drugs. They have ... a new target for anti-tumor agents. , ... Professor Stephan Sieber of the Technische Universitt Mnchen ... a potential new weapon in the fight against ...
Breaking Biology News(10 mins):Contaminated water linked to pregnancy complications, BU study finds 2On the trail of the truffle flavor 2Cancer therapy: Driving cancer cells to suicide 2
... minds about the head size of an ancient human ancestor, ... may have been. Found in Gona, Ethiopia, not far from ... of the famed Australopithecus afarensi "Lucy," the pelvis indicates that ... ago, had a larger birth canal than originally suspected and ...
... , 2008 Arbor Vita Corporation (AVC), a ... its rapid, point-of-care prototype HPV test with a high ... for use throughout the developing world, this diagnostic test ... presentation, "Development of a Rapid Diagnostic Test for Cervical ...
... to make cancer treatment safer A new piece ... (NPL) today will help improve the success rates of ... (linac) will help ensure patients are treated with accurate ... using ionising radiation such as high-energy X-rays or electron ...
Cached Biology News:Arbor Vita presents new data on cancer diagnostic at EUrogin 2NPL unveils new equipment to make cancer treatment safer 2
Required to perform reference file generation, flatfield calibration and performance verification processes on the GSD-501...
ssDNA from PCR DNA in less than 1 hour. No gels, columns, or slurries. Sequence from high quality ssDNA: clearer reads, longer runs....
... of Freezerworks Unlimited includes 2 clients and streamlines ... the sharing of freezers by multiple groups without ... Network Client/Server version for ... monitor with 256 colors; OS 8.6 & OS ...
Applications: Immunohistochemistry, ISH, FISH, CISH....
Biology Products: